Filing Analysis
LifeMD, Inc. announced its financial results for the first quarter ended March 31, 2026, and furnished an updated investor presentation. The filing serves as a routine disclosure of quarterly performance and marketing materials for the investment community.
Key Facts
- Reported financial results for the three months ended March 31, 2026, on May 6, 2026.
- Furnished a press release (Exhibit 99.1) and an investor presentation (Exhibit 99.2).
- The investor presentation is intended for use in meetings with analysts and investors starting May 6, 2026.
- The filing was signed by Chief Financial Officer Atul Kavthekar.
LifeMD announced the resignation of CFO Marc Benathen and the immediate appointment of Atul Kavthekar as his successor. The transition includes a 6-12 month advisory agreement for the outgoing CFO and the promotion of two other executives to C-suite roles.
Red Flags
- Departure of a key financial officer (CFO).
- Significant monthly transition fee ($38,117) for the outgoing CFO, totaling up to $457,404 annually.
Key Facts
- CFO Marc Benathen resigned effective March 31, 2026, to pursue a new opportunity.
- Atul Kavthekar appointed as new CFO effective March 16, 2026, with a $500,000 base salary.
- Outgoing CFO Benathen will receive $38,117 per month for transition advisory services for up to 12 months.
- New CFO Kavthekar was granted 675,000 RSUs, split equally between time-based and performance-based vesting.
- Jessica Friedeman was promoted to Chief Business Officer and Chris Pisano to Chief Marketing Officer.
LifeMD, Inc. announced its financial results for the fourth quarter and full year ended December 31, 2025, and provided earnings guidance for the fiscal year 2026. The company also furnished an updated investor presentation for use in upcoming analyst and investor meetings.
Key Facts
- Reported financial results for the three months and year ended December 31, 2025, on March 9, 2026.
- Issued earnings guidance for the full year 2026.
- Furnished an investor presentation as Exhibit 99.2 to be used starting March 9, 2026.
- The filing was made under Item 2.02 (Results of Operations) and Item 7.01 (Regulation FD Disclosure).